BioCanada

Found 34,478 articles

• Dr. Kieran Murphy Presents Results of Clinical Trial Demonstrating Positive Effect Protecting DNA From Radiation Exposure

  5/26/2023

  Cora Therapeutics, a dynamic life sciences startup based in Toronto, proudly unveils the results of a clinical trial at the Canadian Association of Interventional Radiologists annual meeting in Quebec City.

• Titan Medical Signs License Agreement with Intuitive Surgical

  5/26/2023

  Titan Medical Inc. announced that the Company has entered into a license agreement with Intuitive Surgical, Inc., a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, for an upfront payment of US$7.5 million in respect of certain intellectual property of Titan.

• Medicure Reports Financial Results for Quarter Ended March 31, 2023

  5/26/2023

  Medicure Inc., a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, reported its results from operations for the quarter ended March 31, 2023.

• Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees

  5/26/2023

  Aurinia Pharmaceuticals Inc. announced the filing of a registration statement on Form S-8 with the United States Securities and Exchange Commission.

• Avivagen Announces Significant Increase in Sales to an Existing Customer

  5/25/2023

  Avivagen Inc. is pleased to announce that an existing customer has placed an order sized at 400% of its normal monthly order volume.

• BriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp.

  5/25/2023

  BriaCell Therapeutics Corp. is pleased to announce that it has entered into an arrangement agreement dated May 24, 2023 with BriaPro Therapeutics Corp., a wholly-owned subsidiary of the Company pursuant to which certain pre-clinical pipeline assets of the Company, including Bria-TILsRx™ and protein kinase C delta inhibitors for multiple indications including cancer, will be spun-out to SpinCo by way of a court approved statutory plan of arrangement under the Business Corporations Act .

• Congruence Therapeutics Announces Presentations at the 2023 European and North America CCG UGM & Conferences

  5/25/2023

  Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding, announced oral and poster presentations during the upcoming Chemical Computing Group meetings:

• Sirona Biochem Engages Atheln Inc. to Strengthen Business Development Initiatives

  5/25/2023

  Sirona Biochem Corp. is pleased to announce it has contracted Atheln Inc., a leading US consulting firm, to bolster and facilitate Sirona's business activities.

• Covalon Announces Second Quarter Results for Fiscal 2023

  5/25/2023

  Covalon Technologies Ltd., an advanced medical technologies company, announced its second quarter fiscal 2023 results.

• Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering

  5/25/2023

  Achieve Life Sciences, Inc. announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 3,000,000 shares of common stock at a price of $5.50 per share in a registered direct offering.

• Microbiome Insights Launches Cutting-Edge Metatranscriptomic Sequencing Services

  5/25/2023

  Microbiome Insights Inc., a global leader in microbial sequencing and bioinformatic analysis, is pleased to announce the launch of its new metatranscriptomic sequencing services.

• Numinus Aligns Business Initiatives to Prepare for Future Approval of MDMA-Assisted Therapy

  5/25/2023

  Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF) is pleased to announce several recent initiatives aimed at best positioning the company for the expected FDA approval of MDMA-assisted therapy ("MDMA-AT") in the United States in the first half of 2024.

• Kane Biotech Announces FDA 510(k) Clearance for its coactiv+™ Antimicrobial Wound GelKane’s first FDA cleared medical device aims to disrupt global wound care hydrogel market

  5/25/2023

  Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces that on May 24, 2023 it received 510(k) clearance of its coactiv+™ Antimicrobial Wound Gel from the U.S. Food and Drug Administration (FDA) for the management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1st and 2nd degree burns.

• Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023

  5/25/2023

  Theratechnologies Inc. announced preliminary efficacy data from a Phase 1 study of its lead investigational peptide-drug conjugate candidate, sudocetaxel zendusortide, in patients with advanced solid tumors.

• Kane Biotech Announces First Quarter 2023 Financial Results

  5/25/2023

  Kane Biotech Inc., a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, announced its first quarter 2023 financial results.

• Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract

  5/25/2023

  Oncolytics Biotech® Inc. announced positive results from BRACELET-1, a randomized phase 2 trial in HR+/HER2- metastatic breast cancer.

• Aptose Enters into $25 Million Committed Equity Facility

  5/25/2023

  Aptose Biosciences Inc., a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, announced that it has entered into a common share purchase agreement and registration rights agreement with an institutional investor.

• BioSyent Declares Second Quarter 2023 Dividend

  5/25/2023

  BioSyent Inc. is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on June 15, 2023, to shareholders of record at the close of business on June 2, 2023.

• Therma Bright Expands U.S. Distribution of Venowave Device to Increase Sales Under Temporary CPT(R) & HCPCS Codes

  5/25/2023

  Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that the Company is working with its U.S distributor network

• Brain Cancer Canada Grants Research Funds to Improve Survival Rates for Glioblastoma and Other Gliomas

  5/25/2023

  Brain Cancer Canada, a leading charity in the fight against brain cancer, is delighted to announce a $50,000 research grant to Dr. Amit Singnurkar at Sunnybrook Health Sciences Centre.